Forgiveness of an intermittent HIV treatment strategy
- PMID: 35120635
- DOI: 10.1016/S2352-3018(21)00322-2
Forgiveness of an intermittent HIV treatment strategy
Conflict of interest statement
J-JP has received speaking, advising fees, and research grants to his Institution from Gilead Sciences, Merck Sharp and Dohme, and ViiV Healthcare. JEH has received advising fees from Merck.
Comment on
-
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.Lancet HIV. 2022 Feb;9(2):e79-e90. doi: 10.1016/S2352-3018(21)00300-3. Lancet HIV. 2022. PMID: 35120640 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical